Clinical research is at the heart of all medical advances and contributes greatly to improving the quality of medicine that is available to you and your loved ones. Participants in research studies — people just like you — are a critical link to making these discoveries possible.
Austin Regional Clinic (ARC) is currently enrolling patients in the below studies. Both ARC patients and non-ARC patients who fit trial eligibility requirements are welcome to apply.
ARC Clinical Research enrolling studies
- BaxDuo Pacific Chronic Kidney Disease (CKD) Clinical Study: A phase III, randomized, double-blind, active-controlled study intended to assess the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease (CKD) progression and cardiovascular events in participants with CKD and high blood pressure.
- Chronic Spontaneous Urticaria (CSU) Clinical Study: This study evaluates the efficacy and safety of EV0756 in people with moderate to severe CSU. CSU is a condition where people have hives and local skin swelling that can show up anywhere on the body and last for six weeks or longer.
- ENABLE Multiple Sclerosis (MS) Clinical Study: A long-term observational registry study for patients with multiple sclerosis (MS) to collect real-world data on BRIUMVI (infusion medication) and assess efficacy, safety, and tolerability of medication.
Learn more by calling ARC Clinical Research at 737-247-7240 or visit ARCclinicalresearch.com.